Cargando…

Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study

OBJECTIVES: Patients with schizophrenia treated with clozapine are at risk of acute myocarditis and dilated cardiomyopathy. However, there are no data on the prevalence of subclinical cardiomyopathy or its associations. METHODS: 100 consecutive patients with schizophrenia treated with clozapine for...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, V, Yeoh, T, Ng, A C C, Pasqualon, T, Scott, E, Plater, J, Whitwell, B, Hanzek, D, Chung, T, Thomas, L, Celermajer, D S, Kritharides, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195917/
https://www.ncbi.nlm.nih.gov/pubmed/25332789
http://dx.doi.org/10.1136/openhrt-2013-000030
_version_ 1782339383901290496
author Chow, V
Yeoh, T
Ng, A C C
Pasqualon, T
Scott, E
Plater, J
Whitwell, B
Hanzek, D
Chung, T
Thomas, L
Celermajer, D S
Kritharides, L
author_facet Chow, V
Yeoh, T
Ng, A C C
Pasqualon, T
Scott, E
Plater, J
Whitwell, B
Hanzek, D
Chung, T
Thomas, L
Celermajer, D S
Kritharides, L
author_sort Chow, V
collection PubMed
description OBJECTIVES: Patients with schizophrenia treated with clozapine are at risk of acute myocarditis and dilated cardiomyopathy. However, there are no data on the prevalence of subclinical cardiomyopathy or its associations. METHODS: 100 consecutive patients with schizophrenia treated with clozapine for >1 year and without a history of cardiac pathology (group 1), 21 controls with a history of schizophrenia treated with non-clozapine antipsychotics for >1 year (group 2) and 20 controls without schizophrenia (group 3) were studied. Comprehensive evaluation by clinical examination, ECG, transthoracic echocardiography including left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) and biochemical profiles were performed. RESULTS: Patients with schizophrenia were of similar age, but had higher body mass index (BMI), rates of smoking and hyperlipidaemia than controls. Patients with schizophrenia had received clozapine or non-clozapine antipsychotics for a mean duration of 6.8±5.3 and 9.7±6.1 years, respectively. Patients taking clozapine demonstrated globally impaired LVEF (58.3%: group 1 vs 62.2%: group 2 vs 64.8%: group 3, p<0.001) and GLS (−16.7%: group 1 vs −18.6%: group 2 vs −20.2%: group 3, p<0.001). Moreover, LVEF was <50% in 9/100 (9%) patients receiving clozapine and in non-clozapine schizophrenia patients or healthy controls, but this was not statistically significantly different (analysis of covariance, p=0.19). Univariate analysis in patients taking clozapine found that impaired LV was not predicted by high-sensitivity troponin T, but was associated with features of the metabolic syndrome (including increased triglycerides, low high-density lipoprotein cholesterol (HDL-C), high-sensitivity C reactive protein and BMI), elevated neutrophil count, elevated heart rate, smoking and N-terminal probrain natriuretic peptide. In patients taking clozapine, multivariable analysis identified elevated neutrophil count and low HDL-C as the only independent predictors of impaired GLS. CONCLUSIONS: Asymptomatic mild LV impairment is common in patients with schizophrenia receiving long-term clozapine treatment and is associated with neutrophilia and low HDL-C.
format Online
Article
Text
id pubmed-4195917
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41959172014-10-20 Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study Chow, V Yeoh, T Ng, A C C Pasqualon, T Scott, E Plater, J Whitwell, B Hanzek, D Chung, T Thomas, L Celermajer, D S Kritharides, L Open Heart Heart Failure and Cardiomyopathies OBJECTIVES: Patients with schizophrenia treated with clozapine are at risk of acute myocarditis and dilated cardiomyopathy. However, there are no data on the prevalence of subclinical cardiomyopathy or its associations. METHODS: 100 consecutive patients with schizophrenia treated with clozapine for >1 year and without a history of cardiac pathology (group 1), 21 controls with a history of schizophrenia treated with non-clozapine antipsychotics for >1 year (group 2) and 20 controls without schizophrenia (group 3) were studied. Comprehensive evaluation by clinical examination, ECG, transthoracic echocardiography including left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) and biochemical profiles were performed. RESULTS: Patients with schizophrenia were of similar age, but had higher body mass index (BMI), rates of smoking and hyperlipidaemia than controls. Patients with schizophrenia had received clozapine or non-clozapine antipsychotics for a mean duration of 6.8±5.3 and 9.7±6.1 years, respectively. Patients taking clozapine demonstrated globally impaired LVEF (58.3%: group 1 vs 62.2%: group 2 vs 64.8%: group 3, p<0.001) and GLS (−16.7%: group 1 vs −18.6%: group 2 vs −20.2%: group 3, p<0.001). Moreover, LVEF was <50% in 9/100 (9%) patients receiving clozapine and in non-clozapine schizophrenia patients or healthy controls, but this was not statistically significantly different (analysis of covariance, p=0.19). Univariate analysis in patients taking clozapine found that impaired LV was not predicted by high-sensitivity troponin T, but was associated with features of the metabolic syndrome (including increased triglycerides, low high-density lipoprotein cholesterol (HDL-C), high-sensitivity C reactive protein and BMI), elevated neutrophil count, elevated heart rate, smoking and N-terminal probrain natriuretic peptide. In patients taking clozapine, multivariable analysis identified elevated neutrophil count and low HDL-C as the only independent predictors of impaired GLS. CONCLUSIONS: Asymptomatic mild LV impairment is common in patients with schizophrenia receiving long-term clozapine treatment and is associated with neutrophilia and low HDL-C. BMJ Publishing Group 2014-02-26 /pmc/articles/PMC4195917/ /pubmed/25332789 http://dx.doi.org/10.1136/openhrt-2013-000030 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Heart Failure and Cardiomyopathies
Chow, V
Yeoh, T
Ng, A C C
Pasqualon, T
Scott, E
Plater, J
Whitwell, B
Hanzek, D
Chung, T
Thomas, L
Celermajer, D S
Kritharides, L
Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title_full Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title_fullStr Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title_full_unstemmed Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title_short Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
title_sort asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195917/
https://www.ncbi.nlm.nih.gov/pubmed/25332789
http://dx.doi.org/10.1136/openhrt-2013-000030
work_keys_str_mv AT chowv asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT yeoht asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT ngacc asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT pasqualont asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT scotte asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT platerj asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT whitwellb asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT hanzekd asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT chungt asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT thomasl asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT celermajerds asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy
AT kritharidesl asymptomaticleftventriculardysfunctionwithlongtermclozapinetreatmentforschizophreniaamulticentrecrosssectionalcohortstudy